Search PubMed⌕ Search

Biomedical subjects

A Murisasco

Publications and source records attributed to A Murisasco.

At least 37 records · Page 2Linked to original sources
PubMed1985

Sequential sodium therapy allows correction of sodium-volume balance and reduces morbidity.

We investigated whether individually adjusting Na+ dialysis levels (Na+Di) combined with Na+ and UFR (ultrafiltration rate) programming, and a sodium/volume model (sequential sodium therapy, SST) can improve the end stage renal failure (ESRD) patient's homeostatic equilibrium intra- and interdialytically. One hundred and fifty patients were included in the study over a one year period. The results show that the patients are divided into two groups: 50 patients respond according to the sodium/volume model developed by F. Gotch [1983]. In this group it is possible to predict pre- and post dialysis plasma Na+ concentration (Na+o, Na+t) as a function of Na+Di and it becomes possible to choose Na+Di to allow Na+o and Na+t to virtually coincide, eliminating severe shifts in plasma tonicity. In the second group two subgroups can be distinguished: excess Na+ or excess H2O post dialysis, without possible correction at a single sodium level. SST corrects sodium/volume balance in this group by using sequential intermittent hypo or hypertonic dialysate, combined with fluid removal adapted to each episode. In both groups there was a significant improvement in the clinical condition of the patients who previously were less equilibrated. It is possible to conclude that SST improves tolerance intradialytically and achieves better equilibrium interdialytically. Implementation of SST requires precise control of the concentrate and the water, and equipment adapted for accurate, programmable sequential control of Na+Di and ultrafiltration rate.

Adolescent↗
PubMed1983

Partial purification of a calcium ionophore from human uremic plasma and normal urine.

A fraction is isolated from human uremic plasma and normal urine using a three step chromatographic separation :gel permeation on Sephadex G15, then chromatography on hydroxyapatite and finally desalting operation on Sephadex G15. The fraction thus separated is ninhydrine positive and uncouples mitochondria principally releasing the resting respiration. Calcium potentiates the uncoupling, while red ruthenium and magnesium inhibit it. These results are in good agreement with a ionophorous activity of the isolated fraction. An hypothetic physiological role of this compound is there being discussed.

Animals↗
PubMed1983

Inhibition in vitro of the polymerization of tubulin by uremic middle molecules: corrective effect of isaxonine.

The polymerization of tubulin leads to the formation of microtubules which are one of the components of the axons of nerve cells. This reaction is the limiting factor in the growth of axons. Uremic middle molecules inhibit in vitro the polymerization of tubulin in a dose dependent way. It is possible that a similar phenomenon could occur in vivo in uremic patients, and this might be involved in the development of neuropathy. In addition, isaxonine phosphate counteracts the inhibitory effect of uremic middle molecules on the polymerization of tubulin.

Adult↗
PubMed1982

[Pharmacokinetics of intravenous mezlocillin in patients with normal and impaired renal function (author's transl)].

The pharmacokinetics of mezlocillin after intravenous infusion of 5 g over 30 minutes was compared in 15 patients divided into 3 groups. Group I patients had normal renal function, group II patients had moderate chronic renal impairment and group III patients were under haemodialysis. Plasma mezlocillin levels were measured by the microbiological method. Plasma kinetic values were calculated from a linear two-compartment model, using global estimation of macroconstants by the non-linear least square method. The elimination half-life was 1.19 +/- 0.107 h in group I patients 1.98 +/- 0.19 h in group II patients and 2.34 +/- 0.11 h in group III patients. Renal impairment did not significantly alter the apparent volume of distribution but influenced the total plasma clearance which was 139 +/- 9 ml/min, 87 +/- 9 ml/min and 61 +/- 8 ml/min in groups I, II and III patients respectively. There was a slight decrease of V1 (central compartment) and a noticeable increase of V2 (peripheral compartment), depending on the degree of renal impairment. The total volume of distribution (V1 + V2) remained relatively constant between 12 and 14 litres. Homogeneous results were obtained in each group of patients, thus confirming the regularity of the mezlocillin kinetic model at the dose administered. This should enable dosage adjustment according to renal function, as assessed by laboratory criteria.

Adult↗
PubMed1982

A study of the cardiotoxicity of uremic middle molecules on embryonic chick hearts.

Ultrafiltrates from uremic patients can induce, in vitro, strong modifications of beating frequency of auricular fragments of the embryonic chick heart. According to concentration, effects increase from tachycardia to cessation of cardiac beats. Complete reversion is always observed after washing with normal medium. Only fraction 7c of middle molecules exhibits this cardiotoxicity, other fractions are without effect, even in high concentration. Uremic middle molecules strongly modify cardiac beats in vitro.

Animals↗
PubMed1981

[Acute leukaemia during immunosuppressive treatment. One case (author's transl)].

A 55-year-old man was treated during 22 months with chlorambucil (total dose : 4 218 g) for glomerulonephritis. Towards the end of the treatment, he developed acute myelomonocytic leukaemia and died of this complication. The authors underline the oncogenetic dangers of the association dysimmune disease/immunosuppressive treatment and draw attention to the almost regular preleukaemic phase with its well-known cytological, biochemical, immunological, cytogenetic and evolutive criteria.

Blood Cell Count↗
PubMed1981

Some aspects of middle molecules toxicity.

Middle molecules can act on several levels of uremic disease. So, this work is a multidisciplinary one with the participation of nephrologists, hematologists and also pharmacologists, chemists and biophysicians. We present here our results on four different toxic effects found with middle molecules: the energy dependant phenomena, the platelet aggregability, the cardiotoxic, and the neurotoxic effects. Middle molecules were isolated from urine of normal subjects and blood of patients with chronic renal insufficiency and treated by hemodialysis. Separation was done according to Furst's procedure.

Animals↗
PubMed1981

[Modifications of pure pancreatic secretion in patients with chronic renal failure treated by hemodialysis (author's transl)].

In 20 patients suffering from chronic renal failure treated by hemodialysis (CRFH) the pure pancreatic juice (PPJ) collected via endoscopic cannulation of the papilla was studied. PPJ was collected during 20 minutes in 1 minute samples. Secretin and pancreozymin (CCK-PZ) were given as boluses respectively at the beginning and at the 10th minute of the test. Volumes, total protein and bicarbonate concentrations, total protein and bicarbonate outputs, Lactoferrin (LF) levels were measured. The results observed in patients were compared to those of ten subjects free of any organic disease. The volume of PPJ was significantly more important in CRFH than in controls. Bicarbonate and protein concentrations were not significantly modified. Protein output was not significantly more important in CRFH at the exception of the 12th sample. Bicarbonate output was not significantly increased at the exception of the 9th and the 11th samples. LF level was more than 0.03% of total proteins in 4 CRFH.

Adult↗
PubMed1980

"In vitro" inhibition of platelet aggregation by uremic middle molecules.

"Uremic middle molecules" are isolated from the urine of normal subjects and the blood in chronic renal insufficiency treated by hemodialysis. Their action is tested in vitro on platelets aggregation induced by ADP. Some fractions of these middle molecules (fractions 7b, 7c and 7 "fg") are without any effect. The 7 "de" fractions give an inhibition of platelets aggregation. The percentage variations of first phase inhibition as a function of the middle molecules concentrations is studied.

Adenosine Diphosphate↗
PubMed1979

Action of middle molecules from chronic renal insufficiency treated by hemodialysis on mitochondrial respiration.

"Middle molecules" are isolated both from the urine of normal subjects and from the blood of patients suffering from chronic renal insufficiency treated by hemodialysis. Their action is tested on mitochondrial respiratory activity. Some of these molecular species (fraction 7 f and 7 g) are without any effect. On the other hand the 7 c middle molecules fraction gives a loss of respiratory control due to a decrease of respiratory activity in state 3. A diminution of the P/O ratio is noted and so the available ATP pool is decreased. This action can be compared to the fact that 7 c plasmatic fraction concentration seems to be connected with the patients clinical condition.

Humans↗
PubMed1975

[Nephrologic criteria for reoperation (in the framework of abdominal surgery)].

38 cases of abdominal surgery in acute renal failure, checked anatomically by reintervention or autopsy, were analyzed. The authors emphasize the frequency of the state of shock (2/3 of the cases) and the misleading nature of local signs. They stress the value of routinely checking creatinine clearance in the preoperative check-up in order to screen for latent renal failure.

Abdomen↗